Skip to content

Vitamin D Binding Protein (Gc) Allele Variation Effects Response to Vitamin D Treatment

Vitamin D Binding Protein (Gc) Allele Variation Effects Response to Vitamin D Treatment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00650780
Acronym
Gc
Enrollment
29
Registered
2008-04-02
Start date
2007-10-31
Completion date
2008-01-31
Last updated
2008-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D Status

Keywords

Viatmin D, 25-hydroxyvitamin D, Vitamin D binding protein

Brief summary

We have just completed a randomized, clinical trial of 100,000 IU Vitamin D3 given as a single dose at the beginning of winter. We found a wide range of responses to the dose. This study proposes that genetic differences account for some of the variation in response of 25(OH)D levels after treatment with oral Vitamin D.

Detailed description

We suspect that the wide range of response is effected by other factors such as variation in Vitamin D binding protein (the major transporter of Vitamin D metabolites). Gc, also known as Vitamin D binding protein (DBP), group specific component, or Gc globulin, is a 52-58 kDa multifunctional plasma protein, synthesized in the liver. The gene encoding for Gc is located on chromosome 4, and three common co-dominant alleles give rise to three phenotypes (Gc1s, Gc1f, and Gc2). Gc binds actin, recruits neutrophil leukocytes and converts into a macrophage- and osteoclast- activating factor. It also is the major transporter of Vitamin D and its' metabolites. Lauridsen et al. showed that Gc phenotype correlates with 25(OH)D levels in a group of postmenopausal women. This study proposes that Gc phenotype accounts for some of the variation in response of 25(OH)D levels after treatment with oral Vitamin D.

Interventions

None listed

Sponsors

Creighton University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
19 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Must be willing to participate with an additional blood draw. * Must have been in the previous study.

Exclusion criteria

* Will not be eligible if not a part of the previous study

Design outcomes

Primary

MeasureTime frame
Gc concentration and phenotypeat 1st visit

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026